Acute promyelocytic leukemia (APL) represents one of the most malignant forms of acute myelogenous leukemia. Despite the aggressiveness of this cancer, it can be effectively cured by two different drugs called all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).
In an article from Stig O. Bøe's group, recently published in the prestigious journal Blood (impact factor 10.558) the authors describe a novel therapeutic mechanism that explains why ATO is particularely effective in curing APL. These findings may provide important clues to how the ATO-based therapy of APL may be further developed and adapted for treatment of other cancers.
First author is Emma Lång, and senior author is Stig O. Bøe, who is heading the "Experimental cancer therapy" group at the Laboratory for Molecular Biology at OUS
The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.
Blood. 2012 Jun 12.
Laboratory for Molecular Biology (headed by Magnar Bjørås)